$63.82
9.36% yesterday
Nasdaq, Mar 31, 10:00 pm CET
ISIN
US8036071004
Symbol
SRPT

Sarepta Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

Sarepta Therapeutics, Inc. Classifications & Recommendation:

Buy
88%
Hold
8%
Sell
4%

Sarepta Therapeutics, Inc. Price Target

Target Price $172.32
Price $63.82
Potential
Number of Estimates 22
22 Analysts have issued a price target Sarepta Therapeutics, Inc. 2026 . The average Sarepta Therapeutics, Inc. target price is $172.32. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 24 analysts: 21 Analysts recommend Sarepta Therapeutics, Inc. to buy, 2 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Sarepta Therapeutics, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Sarepta Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Billion $ 1.90 3.14
52.97% 64.87%
EBITDA Margin 14.30% 37.27%
185.10% 160.64%
Net Margin 11.92% 31.63%
126.37% 165.32%

21 Analysts have issued a sales forecast Sarepta Therapeutics, Inc. 2025 . The average Sarepta Therapeutics, Inc. sales estimate is

$3.1b
Unlock
. This is
64.87% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$3.4b 81.18%
Unlock
, the lowest is
$2.9b 51.65%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $1.9b 52.97%
2025
$3.1b 64.87%
Unlock
2026
$3.9b 25.01%
Unlock
2027
$4.2b 6.97%
Unlock
2028
$4.3b 2.58%
Unlock
2029
$4.1b 5.48%
Unlock

6 Analysts have issued an Sarepta Therapeutics, Inc. EBITDA forecast 2025. The average Sarepta Therapeutics, Inc. EBITDA estimate is

$1.2b
Unlock
. This is
329.67% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$1.6b 494.37%
Unlock
, the lowest is
$493m 81.29%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $272m 230.17%
2025
$1.2b 329.67%
Unlock
2026
$2.1b 78.76%
Unlock
2027
$2.5b 21.79%
Unlock
2028
$2.8b 9.84%
Unlock
2029
$2.1b 23.72%
Unlock

EBITDA Margin

2024 14.30% 185.10%
2025
37.27% 160.64%
Unlock
2026
53.29% 42.98%
Unlock
2027
60.67% 13.85%
Unlock
2028
64.97% 7.09%
Unlock
2029
52.43% 19.30%
Unlock

13 Sarepta Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Sarepta Therapeutics, Inc. net profit estimate is

$992m
Unlock
. This is
330.04% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$1.4b 507.73%
Unlock
, the lowest is
$738m 219.93%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $227m 140.34%
2025
$992m 337.39%
Unlock
2026
$1.3b 28.73%
Unlock
2027
$1.5b 18.16%
Unlock
2028
$1.4b 4.15%
Unlock
2029
$1.3b 10.96%
Unlock

Net Margin

2024 11.92% 126.37%
2025
31.63% 165.32%
Unlock
2026
32.57% 2.97%
Unlock
2027
35.98% 10.47%
Unlock
2028
33.62% 6.56%
Unlock
2029
31.67% 5.80%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ 2.34 10.23
140.34% 337.18%
P/E 6.88
EV/Sales 2.17

13 Analysts have issued a Sarepta Therapeutics, Inc. forecast for earnings per share. The average Sarepta Therapeutics, Inc. EPS is

$10.23
Unlock
. This is
329.83% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$14.46 507.56%
Unlock
, the lowest is
$7.61 219.75%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $2.34 140.34%
2025
$10.23 337.18%
Unlock
2026
$13.18 28.84%
Unlock
2027
$15.57 18.13%
Unlock
2028
$14.92 4.17%
Unlock
2029
$13.29 10.92%
Unlock

P/E ratio

Current 29.54 242.64%
2025
6.88 76.71%
Unlock
2026
5.34 22.38%
Unlock
2027
4.52 15.36%
Unlock
2028
4.72 4.42%
Unlock
2029
5.30 12.29%
Unlock

Based on analysts' sales estimates for 2025, the Sarepta Therapeutics, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.59 61.81%
2025
2.17 39.42%
Unlock
2026
1.74 20.01%
Unlock
2027
1.63 6.51%
Unlock
2028
1.59 2.51%
Unlock
2029
1.68 5.80%
Unlock

P/S ratio

Current 3.59 62.69%
2025
2.18 39.35%
Unlock
2026
1.74 20.01%
Unlock
2027
1.63 6.52%
Unlock
2028
1.59 2.51%
Unlock
2029
1.68 5.80%
Unlock

Current Sarepta Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Scotiabank
Locked
Locked
Locked Mar 20 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 19 2025
Cantor Fitzgerald
Locked
Locked
Locked Mar 19 2025
Deutsche Bank
Locked
Locked
Locked Mar 19 2025
Needham
Locked
Locked
Locked Mar 18 2025
Cantor Fitzgerald
Locked
Locked
Locked Mar 18 2025
Scotiabank
Locked
Locked
Locked Mar 07 2025
Analyst Rating Date
Locked
Scotiabank:
Locked
Locked
Mar 20 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 19 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Mar 19 2025
Locked
Deutsche Bank:
Locked
Locked
Mar 19 2025
Locked
Needham:
Locked
Locked
Mar 18 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Mar 18 2025
Locked
Scotiabank:
Locked
Locked
Mar 07 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today